Human Gut Immune Co-Culture
A high-throughput, human-relevant co-culture model that simulates healthy and inflamed gut conditions for evaluating anti-inflammatory drugs.
Innate Immunity Meets the Gut Epithelium: A Translational Inflammation Model
RepliGut® Planar Transverse Colon – THP1 Co-Culture combines primary human intestinal epithelial cells with THP-1 derived macrophages to recreate the immune-epithelial interface of the colon. Built on the RepliGut® Planar platform, this high-throughput system models both healthy and inflamed gut environments using LPS + IFN-γ stimulation. Researchers can assess epithelial damage, barrier disruption, and cytokine responses in a human-relevant context. Co-treatment with FDA-approved IBD therapies adalimumab or tofacitinib attenuates these effects, confirming the utility RepliGut® – THP-1 Co-Culture provides for screening anti-inflammatory therapeutics
Differentiated human colon epithelial cells are cultured on 96-well Transwell® plates and co-cultured with PMA differentiated THP-1 derived macrophages in the basal chamber. Inflammation is triggered via LPS and IFN-γ, activating macrophages and disrupting epithelial integrity. This co-culture captures hallmarks of innate immune activation – including TEER loss, cell viability reduction, and cytokine release.
Differentiated human colon epithelial cells are cultured on 96-well Transwell® plates and co-cultured with PMA differentiated THP-1 derived macrophages in the basal chamber. Inflammation is triggered via LPS and IFN-γ, activating macrophages and disrupting epithelial integrity. This co-culture captures hallmarks of innate immune activation – including TEER loss, cell viability reduction, and cytokine release. Co-treatment with adalimumab or tofacitinib attenuates these effects, confirming its utility for screening anti-inflammatory therapeutics.
Built for Impactful Discovery
Models both healthy and inflamed gut states
Human-relevant: primary colon cells and THP-1-derived macrophages
Quantitative endpoints: TEER, viability, and cytokine release
Lot-to-lot reproducibility
High-throughput 96-well format
Validated with FDA-approved IBD drugs
Macrophage Activation Drives Barrier Breakdown
LPS + IFN-γ stimulation in co-culture triggers a dramatic drop in TEER, modeling gut inflammation.
Clinically Approved IBD Drugs Prevent Barrier Breakdown
Adalimumab and tofacitinib maintain barrier integrity in the co-culture model under inflammatory conditions.
Applications
Models both healthy and inflamed gut states
Investigate epithelial-immune interactions in intestinal disease
Identify immune relevant biomarkers or mechanisms of epithelial injury and repair
Resources
Poster Presentation @ DDW 2025 [file: DDW 2025 Altis RepliGut Co-culture Poster – Final]
Manuscript: Peddibhotla, et al, BioRxiv 2025
Product Information
The RepliGut® Co-Culture – THP-1 96-well kit (CCT-96W) contains a specially formulated co-culture medium and a Transwell® Receiver plate to enable co-culture of THP-1 cells with RepliGut Planar Transverse Colon model (RGP-96W-TC).
Note: THP-1 cells (TIB-202) and associated treatment reagents must be purchased separately.
Product # | Product Name | Contents |
---|---|---|
CCT-96W | RepliGut® Co-Culture – THP-1 – 96 Well Kit | RepliGut® Co-Culture Medium – THP-1, 96-well receiver plate, PBS, 4 sealing strips |
RGP-96W-TC | RepliGut Planar – 96 Well – Transverse Colon Kit | RepliGut® Growth Medium (RGM), RepliGut® Maturation Medium (RMM), 96-well precoated Transwell® culture plate, associated consumables |
AB-C-021 | RepliGut® Co-Culture (THP-1) Procedure | Protocol 🔽 |